Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Silence Therapeutics plc       GB0008433350

SILENCE THERAPEUTICS PLC
My previous session
Most popular
  Report  
No quotes available
-- GBp   --.--%
2013SILENCE THERAPEUTICS PLC : quaterly earnings release
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Silence Therapeutics : Results of Placing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 06:28pm CET

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

For immediate release

Patisserie Holdings PLC

12 October 2018

Results of Placing to raise approximately £15.7m

Further to the earlier announcement in relation to the proposed placing of ordinary shares, the Company announces that 31,451,100 ordinary shares (the 'Placing Shares') have been placed with institutional investors and were placed at a price of 50p per share via an accelerated bookbuild (the 'Placing'). Canaccord Genuity ('Canaccord Genuity')acted as nominated adviser, sole bookrunner and broker in connection with the Placing.The Placing raised approximately £15.7 million before expenses. Application will be made for the admission of 31,451,100 ordinary shares to trading on AIM. It is expected that admission of (a) the Firm Placing Shares comprising 10,000,000 ordinary shares will become effective at 8.00 a.m. on 18 October 2018 and that dealings in the Firm Placing Shares will commence at that time and (b) the Conditional Placing Shares comprising 21,451,100 ordinary shares will become effective at 8.00 a.m. on the Business Day following the General Meeting of the Company (expected to on or around 1 November 2018) and that dealings in the Firm Placing Shares will commence at that time and the Placing Shares shall rank pari passuwith the existing issued ordinary shares of the Company.

Following completion of the Placing the Company will have 135,322,452 Ordinary Shares in issue.

Enquiries

Patisserie Holdings PLC +44 (0)121 777 7000

Luke Johnson, Executive Chairman

Paul May, Chief Executive Officer

Nomad and Broker

Canaccord Genuity Limited +44 (0)20 7523 8000

Chris Connors

Henry Fitzgerald-O'Connor

Financial Public Relations

Maitland +44 (0) 20 7379 5151

Sam Cartwright

Jonathan Cook

Disclaimer

Silence Therapeutics plc published this content on 12 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 October 2018 16:27:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SILENCE THERAPEUTICS PLC
12/11ALNYLAM PHARMACEUTICALS : Silence Therapeutics reaches settlement and licence ag..
AQ
10/13SILENCE THERAPEUTICS : US Patent Trial & Appeal Board (PTAB) Upholds Silence Pat..
AQ
10/12SILENCE THERAPEUTICS : Results of Placing
PU
10/12US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First..
GL
10/12Silence Therapeutics Announces Receipt of a New European Notice of Intention ..
GL
10/11SILENCE THERAPEUTICS : PTAB Upholds Silence Patent
PU
10/10SILENCE THERAPEUTICS : New divisional patent and injunction application
PU
09/27SILENCE THERAPEUTICS : to Present at the Cantor Fitzgerald 2018 Global Healthcar..
AQ
09/27MANAGEMENT TRACKS : Merck clears path for Frazier to remain CEO
AQ
09/26Silence Therapeutics to Present at the Cantor Fitzgerald 2018 Global Healthca..
GL
More news
Financials (GBP)
Sales 2018 14,0 M
EBIT 2018 -
Net income 2018 -
Debt 2018 37,7 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,56x
EV / Sales 2019 3,51x
Capitalization 40,2 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 2,77  GBP
Spread / Average Target 390%
Managers
NameTitle
David Horn Solomon Chief Executive Officer & Director
Andrew John McGlashan Richards Non-Executive Chairman
David J. Ellam CFO, Secretary & Executive Director
Marie W. Lindholm Head-Technology Innovation
Stephen B. Parker Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SILENCE THERAPEUTICS PLC51
IQVIA HOLDINGS INC20.55%23 609
CELLTRION, INC.--.--%23 068
LONZA GROUP14.51%22 493
INCYTE CORPORATION-30.05%14 099
SEATTLE GENETICS, INC.13.05%9 759